Conserving the lymphatics from the arm using fluorescence imaging in patients with breast cancer at high risk of postoperative lymphedema: a pilot study.
Axillary reverse mapping (ARM)
breast neoplasm
fluorescence imaging
indocyanine green (ICG)
lymphedema
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
ppublish
Résumé
Postoperative lymphedema in breast cancer survivors is a serious complication that develops from axillary lymph node dissection (ALND), chemotherapy, and radiation therapy. Axillary reverse mapping (ARM) was recently introduced to reduce lymphedema. This pilot study aimed to investigate the feasibility of preserving the ARM node using fluorescence imaging for patients at high risk of lymphedema. We prospectively screened patients with breast cancer who had pathologic node-positive disease at diagnosis and were scheduled for neoadjuvant chemotherapy (NCT). The sentinel lymph node (SLN) was identified using blue dye and radioisotope, while the ARM node was traced using indocyanine green (ICG). In cases in which SLN was negative on the intraoperative frozen section examination, the ARM node and lymphatics were preserved. Of the 20 screened patients, six whose metastatic axillary lymph node (ALN) was converted to clinically node-negative disease after NCT were enrolled. No patients experienced recurrence at 24 months postoperative. Four patients who had a preserved ARM node did not develop lymphedema. One patient whose ARM node was not preserved due to SLN identification failure did not develop postoperative lymphedema. One patient who underwent ALND without ARM node conservation because of metastatic SLN on frozen section examination developed postoperative lymphedema. ARM is oncologically safe, decreases the incidence of postoperative lymphedema, and allows for the early detection of postoperative lymphedema in patients who underwent ALND. Ultimately, ARM may help improve the quality of life of patients with pathologic node-positive breast cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Postoperative lymphedema in breast cancer survivors is a serious complication that develops from axillary lymph node dissection (ALND), chemotherapy, and radiation therapy. Axillary reverse mapping (ARM) was recently introduced to reduce lymphedema. This pilot study aimed to investigate the feasibility of preserving the ARM node using fluorescence imaging for patients at high risk of lymphedema.
METHODS
METHODS
We prospectively screened patients with breast cancer who had pathologic node-positive disease at diagnosis and were scheduled for neoadjuvant chemotherapy (NCT). The sentinel lymph node (SLN) was identified using blue dye and radioisotope, while the ARM node was traced using indocyanine green (ICG). In cases in which SLN was negative on the intraoperative frozen section examination, the ARM node and lymphatics were preserved.
RESULTS
RESULTS
Of the 20 screened patients, six whose metastatic axillary lymph node (ALN) was converted to clinically node-negative disease after NCT were enrolled. No patients experienced recurrence at 24 months postoperative. Four patients who had a preserved ARM node did not develop lymphedema. One patient whose ARM node was not preserved due to SLN identification failure did not develop postoperative lymphedema. One patient who underwent ALND without ARM node conservation because of metastatic SLN on frozen section examination developed postoperative lymphedema.
CONCLUSIONS
CONCLUSIONS
ARM is oncologically safe, decreases the incidence of postoperative lymphedema, and allows for the early detection of postoperative lymphedema in patients who underwent ALND. Ultimately, ARM may help improve the quality of life of patients with pathologic node-positive breast cancer.
Identifiants
pubmed: 32775252
doi: 10.21037/gs.2020.03.29
pii: gs-09-03-629
pmc: PMC7347801
doi:
Types de publication
Journal Article
Langues
eng
Pagination
629-636Informations de copyright
2020 Gland Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs.2020.03.29). The authors have no conflicts of interest to declare.
Références
Lymphology. 2016 Dec;49(4):170-84
pubmed: 29908550
J Surg Oncol. 2014 May;109(6):612-5
pubmed: 24310418
Breast Cancer Res Treat. 2010 Feb;119(3):529-35
pubmed: 19842033
Cathet Cardiovasc Diagn. 1989 Aug;17(4):231-3
pubmed: 2670244
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
Ann Surg Oncol. 2007 Sep;14(9):2490-6
pubmed: 17549570
Breast Cancer Res Treat. 2010 Jun;121(2):373-8
pubmed: 20140704
Ann Surg Oncol. 2007 Jun;14(6):1890-5
pubmed: 17479341
Ann Surg Oncol. 2014 Apr;21(4):1254-9
pubmed: 24356798
PLoS One. 2016 Feb 26;11(2):e0150285
pubmed: 26919589
Breast Cancer. 2008;15(1):5-7
pubmed: 18224386
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
Eur J Surg Oncol. 2015 Apr;41(4):442-9
pubmed: 25704555
J Clin Oncol. 2015 Jan 20;33(3):258-64
pubmed: 25452445
Ann Surg. 2017 May;265(5):987-992
pubmed: 27163955
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Lancet. 1997 Jun 28;349(9069):1864-7
pubmed: 9217757
J Natl Compr Canc Netw. 2016 Mar;14(3):324-54
pubmed: 26957618
Breast Cancer Res Treat. 2017 Nov;166(2):473-480
pubmed: 28766131
Cancers (Basel). 2010 Apr 27;2(2):713-20
pubmed: 24281090
J Surg Oncol. 2018 Mar;117(3):336-340
pubmed: 29228459
Breast. 2013 Jun;22(3):357-61
pubmed: 23022046
Cancer Res Treat. 2018 Jul;50(3):801-812
pubmed: 28814071
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
Ann Surg Oncol. 2013 Sep;20(9):2858-65
pubmed: 23645483